Department of Molecular Biology and Genetics, Biotechnology Building, Cornell University, Ithaca, New York 14853-2703, USA.
Biochemistry. 2010 Jun 15;49(23):4841-51. doi: 10.1021/bi100119t.
Gamma-aminobutyric acid type A receptors (GABA(A) receptors) are ligand-gated chloride channels that play a central role in signal transmission within the mammalian central nervous system. Compounds that modulate specific GABA(A) receptor subtypes containing the delta-subunit are scarce but would be valuable research tools and starting points for potential therapeutic agents. Here we report a class of dihydropyrimidinone (DHPM) heterocycles that preferentially potentiate peak currents of recombinant GABA(A) receptor subtypes containing the delta-subunit expressed in HEK293T cells. Using the three-component Biginelli reaction, 13 DHPMs with structural features similar to those of the barbiturate phenobarbital were synthesized; one DHPM used (monastrol) is commercially available. An up to approximately 3-fold increase in the current from recombinant alpha1beta2delta receptors was observed with the DHPM compound JM-II-43A or monastrol when co-applied with saturating GABA concentrations, similar to the current potentiation observed with the nonselective potentiating compounds phenobarbital and tracazolate. No agonist activity was observed for the DHPMs at the concentrations tested. A kinetic model was used in conjunction with dose-dependent measurements to calculate apparent dissociation constant values for JM-II-43A (400 muM) and monastrol (200 microM) at saturating GABA concentrations. We examined recombinant receptors composed of combinations of subunits alpha1, alpha4, alpha5, alpha6, beta2, beta3, gamma2L, and delta with JM-II-43A to demonstrate the preference for potentiation of delta-subunit-containing receptors. Lastly, reduced currents from receptors containing the mutated delta(E177A) subunit, described by Dibbens et al. [(2004) Hum. Mol. Genet. 13, 1315-1319] as a heritable susceptibility allele for generalized epilepsy with febrile seizures plus, are also potentiated by these DHPMs.
γ-氨基丁酸 A 型受体 (GABA(A) 受体) 是配体门控氯离子通道,在哺乳动物中枢神经系统内的信号转导中发挥核心作用。调节含有 δ 亚基的特定 GABA(A) 受体亚型的化合物稀缺,但将是有价值的研究工具和潜在治疗剂的起点。本文报告了一类二氢嘧啶酮 (DHPM) 杂环,它们优先增强在 HEK293T 细胞中表达的含有 δ 亚基的重组 GABA(A) 受体亚型的峰值电流。使用三组分 Biginelli 反应,合成了 13 种具有与巴比妥酸类似结构特征的 DHPM;一种使用的 DHPM(单司他隆)是市售的。在与饱和 GABA 浓度共同应用时,DHPM 化合物 JM-II-43A 或单司他隆观察到对重组 α1β2δ 受体的电流增加约 3 倍,类似于观察到的非选择性增强化合物苯巴比妥和特拉唑嗪的电流增强。在测试浓度下,DHPM 没有表现出激动剂活性。使用动力学模型结合剂量依赖性测量来计算在饱和 GABA 浓度下 JM-II-43A(400 μM)和单司他隆(200 μM)的表观解离常数值。我们检查了由亚基 α1、α4、α5、α6、β2、β3、γ2L 和 δ 组成的组合的重组受体与 JM-II-43A 一起,以证明对含有 δ 亚基的受体的增强作用的偏好。最后,由 Dibbens 等人描述的含有突变 δ(E177A)亚基的受体的电流减少([2004]Hum.Mol.Genet.13,1315-1319)也被这些 DHPM 增强。